Impact of an Early and Extended Rehabilitation Program Combining Individually Tailored Nutrition and Physical Activities on Patient Outcomes After Invasive Mechanical Ventilation and Vasopressor Therapy in the ICU
Launched by NANTES UNIVERSITY HOSPITAL · Aug 29, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The NUTRIREA-4 trial is studying whether a special rehabilitation program can help patients recover better after being on a ventilator and receiving medications for shock in the ICU. This program includes personalized nutrition, physiotherapy, and physical activities, starting early in the ICU and continuing at home after leaving the hospital. The goal is to see if this tailored approach leads to improved long-term health outcomes compared to the usual care that patients typically receive.
To participate in this trial, patients need to be 18 years or older, have started using a ventilator within the last 24 hours, and be receiving treatment for shock. They should also be able to give consent or have their family involved in the decision. Participants will either receive the early rehabilitation program or the standard care provided in their ICU. This trial is currently recruiting patients, and it aims to help improve recovery for those who have faced critical illnesses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Invasive mechanical ventilation (MV) started in the ICU within the past 24 h, or started before ICU admission with ICU admission within the past 24 h, and expected to be required for at least 48 hours after randomization
- • Treatment with a vasoactive agent for shock (adrenaline, dobutamine, or noradrenaline)
- • Nutritional support expected to be started within 24 h after intubation (or within 24 h after ICU admission if intubation occurred before ICU admission)
- • Age 18 or older
- • Patient and/or next-of-kin informed about the trial and having consented to participation in the trial. If the patient is unable to receive information and no next-of-kin can be contacted during screening for the trial, trial inclusion will be completed as an emergency procedure by the ICU physician, in compliance with French law.
- • Covered by the French public health-insurance system
- Exclusion Criteria:
- • MV started more than 24 hours earlier
- • Specific nutritional needs, such as pre-existing long-term home enteral or parenteral nutrition for chronic bowel disease
- • Dying patient, do-not-resuscitate order, or other treatment- limitation decision at ICU admission
- • Social circumstances hindering follow-up and telephone/video consultations (no fixed address, non-European residence)
- • Inability to provide a stable personal mobile phone number (temporary number or not in the owner's name)
- • Communication difficulties via telephone or video consultation (pre-existing severe hearing or visual impairment)
- • Pre-existing chronic illness with life expectancy \<6 months
- • Pre-existing cognitive impairment
- • Pre-existing spinal injury
- • Inability to walk before the critical illness
- • Acute or chronic neuromuscular disease
- • Brain injury, e.g., due to cardiac arrest, stroke, or severe trauma
- • Pregnancy, recent delivery, or lactation
- • Adult under guardianship
- • Correctional facility inmate
- • Institutionalized patient
- • Prior inclusion in a randomized trial designed to compare rehabilitation programs delivered to patients during critical illness
About Nantes University Hospital
Nantes University Hospital, a leading academic medical institution in France, is dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific exploration with patient care, fostering collaborations among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Nantes University Hospital aims to contribute to the development of effective therapies and interventions that enhance patient outcomes and overall public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tours, , France
Grenoble, , France
Montpellier, , France
Suresnes, , France
Amiens, , France
Nice, , France
Rennes, , France
Lille, , France
Besançon, , France
Nantes, , France
Clermont Ferrand, , France
Angers, , France
Reims, , France
Valenciennes, , France
Rouen, , France
Dijon, , France
Lyon, , France
Argenteuil, , France
Dieppe, , France
Strasbourg, , France
Saint Priest En Jarez, , France
Lens, , France
Le Mans, , France
Vannes, , France
Bordeaux, , France
Tarbes, , France
Cholet, , France
Saint Denis, , France
Verdun, , France
Belfort, , France
Haguenau, , France
Strasbourg, , France
Béthune, , France
Paris, , France
Saint Malo, , France
Orléans, , France
Paris, , France
Albi, , France
Amiens, , France
Angoulême, , France
Garches, , France
La Roche Sur Yon, , France
Le Kremlin Bicêtre, , France
Lomme, , France
Lorient, , France
Melun, , France
Paris, , France
Paris, , France
Paris, , France
Saint Brieuc, , France
épagny, , France
Nice, , France
Patients applied
Trial Officials
Jean REIGNIER, MD, PhD
Principal Investigator
Nantes University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported